<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758949</url>
  </required_header>
  <id_info>
    <org_study_id>FL-101-2001</org_study_id>
    <nct_id>NCT04758949</nct_id>
  </id_info>
  <brief_title>FL-101 in Surgically Resectable Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients With Surgically Resectable Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flame Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flame Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 trial to study FL-101 alone or in combination with nivolumab in patients who have&#xD;
      surgically resectable Non-Small Cell Lung Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 2-Cohort, Phase 2, multicenter, parallel-design trial that will study patients with&#xD;
      surgically resectable, stages I-IIIA, non-small cell lung cancer (NSCLC) . The clinical study&#xD;
      will focus on whether FL-101 has direct anti-tumor activity when given alone prior to&#xD;
      surgery, and if FL-101 improves the anti-tumor response when given in combination with&#xD;
      nivolumab prior to surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Cohort 2 will be randomized. The investigator and participants will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment related adverse events as assessed by NCI CTCAE v.5.0</measure>
    <time_frame>From time of first dose to 3 months after surgery</time_frame>
    <description>To evaluate the tolerability, incidence and severity of AEs and SAEs graded according to NCI CTCAE v5.0 of FL-101 as monotherapy and in combination with nivolumab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment efficacy as assessed by pathological response (percentage of residual tumor) by independent pathology review.</measure>
    <time_frame>At time of surgery (around 6-8 weeks)</time_frame>
    <description>Cohort 1: To evaluate the activity of FL-101 neoadjuvant monotherapy in patients with Stage IA3 or IB NSCLC&#xD;
Cohort 2: To evaluate the effect of FL-101 in combination with nivolumab compared to nivolumab plus placebo in neoadjuvant therapy in patients with Stage II-IIIA NSCLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Pathologic Response</measure>
    <time_frame>At time of surgery (around 6-8 weeks after first dose)</time_frame>
    <description>To determine major pathologic response (MPR), defined as ≤10 percent viable tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Pathologic Response</measure>
    <time_frame>At time of surgery (around 6-8 weeks after first dose)</time_frame>
    <description>To estimate complete pathologic response (CPR), defined as the absence of residual invasive cancer in resected lung specimens and lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>At time of surgery (around 6-8 weeks after first dose)</time_frame>
    <description>To estimate objective response rate (ORR) by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD measurement by ctDNA</measure>
    <time_frame>From time of first dose to 3 months after surgery</time_frame>
    <description>To describe the time course of minimal residual disease (MRD) response by ctDNA and recurrence in correlation with clinical response</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma Concentration of FL-101</measure>
    <time_frame>From time of first dose up to 3 months after surgery</time_frame>
    <description>To evaluate the pharmacokinetics of FL-101 in patients with NSCLC</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma IL-1β/IL-6 levels</measure>
    <time_frame>From time of first dose up to 3 months after surgery</time_frame>
    <description>To evaluate the effect of FL-101 on pharmacodynamic biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum hsCRP</measure>
    <time_frame>From enrollment up to 3 months after surgery</time_frame>
    <description>To evaluate the effect of FL-101 on pharmacodynamic biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence and incidence of Anti-FL-101 antibodies</measure>
    <time_frame>From time of first dose up to 3 months after surgery</time_frame>
    <description>To evaluate possible immunogenicity of FL-101</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>FL-101 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients will receive FL-101 prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FL-101 + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients will receive FL-101 and Nivolumab prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 patients will receive Nivolumab and placebo prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FL-101</intervention_name>
    <description>200 mg administered intravenously every 2 weeks prior to surgery.</description>
    <arm_group_label>FL-101 + Nivolumab</arm_group_label>
    <arm_group_label>FL-101 Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>240 mg administered intravenously every 2 weeks prior to surgery.</description>
    <arm_group_label>FL-101 + Nivolumab</arm_group_label>
    <arm_group_label>Nivolumab + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>200 mg administered intravenously every 2 weeks prior to surgery.</description>
    <arm_group_label>Nivolumab + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Previously untreated and pathologically confirmed, surgically resectable Stage IA3,&#xD;
             IB, II, or IIIA NSCLC of squamous or non-squamous histology.&#xD;
&#xD;
          2. ≥1 radiologically measurable tumor &gt;2cm in diameter.&#xD;
&#xD;
          3. Smoking history ≥10 pack years.&#xD;
&#xD;
          4. Available tissue block for analysis from a core needle biopsy(or similar sample)&#xD;
&#xD;
          5. High-sensitivity C-reactive protein (hsCRP) level ≥2 mg/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior exposure to chemotherapy, radiotherapy or systemic anti-cancer therapy&#xD;
             (e.g., monoclonal antibody therapy) for lung cancer.&#xD;
&#xD;
          2. Malignancies other than NSCLC within 2 years prior to Cycle 1, Day 1, with the&#xD;
             exception of those with a negligible risk of metastasis or death and with expected&#xD;
             curative outcome&#xD;
&#xD;
          3. Currently participating in, or has participated in, a trial of an investigational&#xD;
             agent within 4 weeks prior to the first dose of study treatment or 5 half-lives,&#xD;
             whichever is longer and with recovery of clinically significant toxicities from that&#xD;
             therapy.&#xD;
&#xD;
          4. Tumors known to express driver mutations of the EGFR or ALK pathways.&#xD;
&#xD;
          5. Known severe hypersensitivity (Grade ≥3) to FL-101, its active substance, or any of&#xD;
             its excipients&#xD;
&#xD;
          6. Known history of human immunodeficiency virus or active Hepatitis B or Hepatitis C&#xD;
             infection&#xD;
&#xD;
        Additional Exclusion Criteria for Patients with Stage II and III Disease&#xD;
&#xD;
          1. Prior treatment with anti-PD-1, anti-CTLA-4, or anti-PD-L1 therapeutic antibody or&#xD;
             pathway-targeting agents&#xD;
&#xD;
          2. Treatment with systemic immunosuppressive medications (including but not limited to&#xD;
             prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor&#xD;
             necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1&#xD;
&#xD;
          3. Known severe hypersensitivity (Grade ≥3) to nivolumab or chemotherapy agents or to any&#xD;
             of their excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cassandra Choe-Juliak, MD</last_name>
    <role>Study Director</role>
    <affiliation>Flame Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Head of Clinical Operations</last_name>
    <phone>1-833-50-FLAME (35263)</phone>
    <email>Clinicaltrials@flame.bio</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Blood &amp; Cancer Specialists</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayley King</last_name>
      <phone>520-290-2510</phone>
      <email>hking@acrcresearch.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Modiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, LLP</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Vigen</last_name>
      <email>sara.vigen@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Murphy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliate Oncologist</name>
      <address>
        <city>Chicago Ridge</city>
        <state>Illinois</state>
        <zip>60415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Malone</last_name>
      <email>angela.malone@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Rami Haddad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Sklow</last_name>
      <phone>718-405-8535</phone>
      <email>charlotte.sklow@einsteinmed.org</email>
    </contact>
    <investigator>
      <last_name>Brendon Stiles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Owens</last_name>
      <email>michelle.owens@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Uyeki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Huntzinger</last_name>
      <email>jonathan.huntzinger@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Kartik Konduri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christy DeCastro</last_name>
      <email>christy.decastro@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Monte Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debora Lind</last_name>
      <email>debora.lind@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Crawley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialist</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carrie Friedman</last_name>
      <email>carrie.friedman@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North West Cancer Specialist</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Papenfuse</last_name>
      <email>susan.papenfuse@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Anthonly Van Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal</name>
      <address>
        <city>Montréal</city>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adeline Jouquan</last_name>
      <phone>1 514 890 8000</phone>
      <phone_ext>26832</phone_ext>
      <email>adeline.jouquan.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Moishe Liberman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kidane</last_name>
      <email>bkidane@hsc.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Biniam Kidane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Monnet</last_name>
      <email>isabelle.monnet@chicreteil.fr</email>
    </contact>
    <investigator>
      <last_name>Issabelle Monnet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Quantin</last_name>
      <email>xavier.quantin@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Quantin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Gentilly</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Spaeth</last_name>
      <email>d.spaeth@ilcgroupe.fr</email>
    </contact>
    <investigator>
      <last_name>Dominique Spaeth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital d'Instruction Des Armees Begin</name>
      <address>
        <city>Saint-Mandé</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helissey</last_name>
      <email>jcarole.helissey@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carole Helissey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Herder</last_name>
      <email>gjm.herder@meandermc.nl</email>
    </contact>
    <investigator>
      <last_name>Judith Herder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis St. Jansdal</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gans</last_name>
      <email>sjm.gans@stjansdal.nl</email>
    </contact>
    <investigator>
      <last_name>Stephanus Gans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kastelijn</last_name>
      <email>l.kastelijn1@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Kastelijn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgically Resectable</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>FL-101</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

